What Is CBG? The "Mother Cannabinoid" Has a Focus Story, a Plausible Receptor, and No Published Focus Benefit

CBG has the best family story on the shelf. Its acid form, CBGA, is the compound cannabis enzymes turn into the acid forms of THC and CBD, which earned it the nickname "mother of all cannabinoids," and somewhere between the botany and the tin the nickname became a promise: focus, calm, energy, no high. The no-high part holds up. The focus part is a marketing position with a plausible receptor behind it and no published benefit in people.

The record is wider than the usual summary of one trial and a survey, and that does the marketing no favors. The only published human study we found that scored attention tasks, 12 adults on 25 to 200mg, reports few effects of any kind. The trial built to settle the question gave 67 adults with ADHD symptoms 80mg or placebo, finished on July 30, 2026, and had posted no results when we read the registry on November 7. Eighty milligrams is eight Wyld Pear gummies, which is also 80mg of THC.

What is CBG?

CBG, or cannabigerol, is a non-intoxicating cannabinoid formed when cannabigerolic acid (CBGA) loses a carboxyl group. Cannabis enzymes turn CBGA into the acid forms of THC and CBD, so ordinary plants hold little CBG: up to about 10 percent of the cannabinoid fraction, against up to 90 percent in cultivars bred for it.

Russo's 2022 survey paper records the nickname, Jastrząb's 2022 review lays out the chemistry, and the chemistry is where the nickname belongs. A biosynthetic pathway tells you where THC comes from. It tells you nothing about what a swallowed gummy does.

Few people have tried it on purpose. In a probability sample of 1,523 US adults, lifetime CBG use was 1.3 percent against 35.2 percent for CBD (Satybaldiyeva 2025). Moore's 2026 paper describes it as increasingly sold for purported attention, focus and memory, and Nachnani's 2021 review had already noted a supplement market with little research behind it.

What did the 20mg CBG trial actually measure?

Self-rated anxiety, stress and mood, in 34 healthy adults who already used cannabis, after one 20mg hemp tincture or placebo a week apart. Anxiety ratings fell slightly more on CBG (p=0.034), stress differed only before the stress test, mood did not differ, and the formal anxiety inventory missed. Attention was not scored on its own.

Cuttler and colleagues ran this over Zoom in Washington State and published it in Scientific Reports in 2024. It is a real double-blind crossover, so read it at its actual size. The 10-point anxiety rating fell 0.95 on CBG, from a baseline of 3.59, and 0.66 on placebo: a gap of 0.29 points in people who were not very anxious to begin with. The State-Trait Anxiety Inventory in the same session showed no main effect of condition (p=0.126), which the authors say dampens enthusiasm. Stress separated at the first reading, about 20 minutes after dosing and before the stressor (p=0.032), and not after the Trier Social Stress Test (p=0.583) or at the end (p=0.142). Mood never left placebo (p=0.081).

The memory line is the surprise. On a 16-word list test, the abstract says "CBG also enhanced verbal memory relative to placebo" (F(1,30)=4.17, p=0.050). In words, that is half a word more on the second learning trial and one word more on the third. The authors hypothesized only that CBG would not impair memory, call the result unexpected, did not correct for multiple comparisons, and write that false positives remain possible.

What it showed cleanly is the absence of a high: intoxication ratings under 2 out of 10 in both arms, and a DRUID impairment score of 43.1 on CBG against an impairment line of 57. That app reports one global score built on reaction time and balance, which rules out impairment and says nothing about sharper attention. The paper lists attention among things future studies should test.

The placebo deserves a mention. It was Chartreuse, the green liqueur from France's Carthusian monks, cut one to one with water to match the tincture's color and herbal taste, then mailed to participants in coded vials.

The last reading came about an hour after dosing, while blood levels in Story's 2024 pharmacokinetic study peaked anywhere from 45 minutes to nearly 2 hours depending on dietary fat. Co-author Russo runs CReDO Science, which formulates CBG.

Who else has given CBG to people?

More groups than most summaries mention. A PubMed search on November 7, 2026 found a 12-adult dose-ranging study, a 63-veteran sleep trial, a 25mg pharmacokinetic study, a CBD-and-CBG soreness pilot and a second user survey. None reports a focus benefit, and the one sleep trial of CBG alone landed level with placebo.

Wolinsky's 2026 study is the one to know. Twelve healthy adults took placebo and 25, 50, 100 and 200mg of CBG isolate in oil, and were followed for eight hours. The matching registry entry, NCT05324982, lists a Divided Attention Task, Digit Symbol Substitution, PASAT and a Digit Vigilance Test among its primary measures. The abstract reports no drug-related adverse events, normal liver tests after the two highest doses, and "few pharmacodynamic or psychoactive effects." The only subjective changes it names are lower Jittery and Active ratings at 50mg, more appetite at 200mg and, at 100mg, a significant drop in Calm. A molecule sold on calm managed that in a 12-person study; we would not build a claim on it either way. We could not get the full text on November 7, so the attention-task tables stay unquoted here.

Emerson's veterans trial, paid for by LEVEL, which makes the tablet it tested, randomized 63 people to placebo or 25mg a day for two weeks and then 50mg for two. Both groups reported better sleep with no significant difference between them, and only 35 finished without a major protocol deviation. It ended in May 2022 and reached a journal in December 2025. One side finding: a lower heart rate two hours after afternoon doses (p=0.017), which is what the next section predicts.

Peters's Canopy Growth pilot gave 50mg of CBG with 35mg of CBD twice a day for soreness, and left objective recovery, sleep and mood unchanged.

The surveys tell you who buys it. Russo's 127 respondents reported treating anxiety, chronic pain, depression and insomnia. Lutz's 239 put insomnia first at 62 percent, then inflammatory pain at 44 and anxiety at 33, at a typical dose of 10 to 12mg. Focus leads neither list. Russo and Cuttler are authors on both. Self-selected buyers are the weakest evidence on this page, and the newer survey still describes a bedtime molecule.

What does CBG's receptor profile predict?

Something calming and faintly sedating, with no high. Cascio's 2010 mouse brain work found CBG activates alpha-2 adrenergic receptors at 0.2 nanomolar, blocks 5-HT1A at about 52 nanomolar and binds cannabinoid receptors with modest affinity. Alpha-2A agonism is how the ADHD drug guanfacine works, which is where the focus story gets its plausibility.

The FDA label for extended-release guanfacine (Intuniv) calls it a central alpha-2A agonist for ADHD and warns of low blood pressure, slow heart rate and sedation. So the honest prediction from that receptor is a steadier, sleepier person with lower blood pressure. It does not predict energy, which is a shelf word. In living mice, injected CBG cut blood pressure by 28 mmHg against 12 for vehicle, blocked by the alpha-2 antagonist atipamezole (Vernail 2022), and reversed chemotherapy nerve pain only where thalamic alpha-2A receptors were intact (Wade 2025).

The potency number is shakier than it looks. The 0.2 nanomolar came from brain membranes; the same paper needed 72.8 nanomolar in an isolated mouse vas deferens, a gap of about 360-fold its authors flagged. In Mendiguren's 2023 rat slices, at 30 micromolar, 150,000 times the membrane figure, CBG barely changed firing in the locus coeruleus, the brain's main noradrenaline hub, and weakened a selective alpha-2 agonist instead of mimicking one, by a mechanism the authors call unknown.

5-HT1A is just as untidy. Cascio calls CBG an antagonist there and CBD is reported as an agonist, and in Rock's 2011 animal experiments every dose of CBG tested reversed CBD's anti-nausea effect. We found no human test of that, which matters if a 1:1:1 gummy is your nausea plan. Yet Mendiguren's rats showed less anxiety on injected CBG, an effect a 5-HT1A blocker prevented, and Cuttler's discussion reaches for the same receptor to explain its anxiety result. The receptor CBG supposedly blocks keeps getting credit for its calm.

The cannabinoid receptors are the simple part, and they are why you do not get high. Navarro's 2018 cell work measured CBG at 1,045 nanomolar for CB1 and 1,225 for CB2 in one binding assay, with no CB1 displacement in a second and 152 nanomolar at CB2 in living cells, where it acted as a partial agonist. THC runs 5 to 80 nanomolar at CB1 in the affinity table on our endocannabinoid piece.

Does CBG help you focus?

No published human trial shows it. The 12-adult dose study scored attention tasks at 25 to 200mg and reported few effects of any kind, and the 67-adult Arkansas trial built around attention and ADHD symptoms finished in July with no results posted. Rat studies point in different directions, and none used a gummy.

The Arkansas record is the one to watch. NCT06115603, registered as The Effects of Cannabigerol on Attention-Deficit/Hyperactivity Disorder, is a phase 2 University of Arkansas trial: one 80mg dose or MCT oil in adults aged 18 to 55 reporting ADHD symptoms, with attention, processing speed, verbal learning and decision tasks at 75 minutes. Enrollment closed at 67, the registry was last updated on November 4, and we found no paper in PubMed or Europe PMC's preprint index on November 7. Washington State's follow-up to Cuttler, 100 adults at 50mg with cortisol and memory testing, ended February 27 and sits in the same position.

The rats split. Moore's Johns Hopkins group gave oral CBG up to 600mg per kilogram; sustained attention fell in females at 300mg per kilogram and above, and the abstract mentions no gain at any dose. A PsyArXiv preprint from McLaughlin's lab, not yet peer reviewed, injected 0.3 to 10mg per kilogram and reported better divided attention at 0.3 and 3mg per kilogram beside mildly worse sustained attention. That is the best news the category has. The same task also showed guanfacine, the approved drug, impairing divided attention, which says something about how far this model travels.

For anyone with a diagnosis, our ADHD page makes the larger point: the cannabinoid with direct evidence on attention is THC, and the evidence runs the wrong way.

The table sets each shelf claim against the receptor data, the human data and the dose.

How much CBG is in a dispensary gummy?

The products we track carry 2 to 10mg, beside THC. Wyld Pear has 10mg of each, Papa and Barkley Pear Apple 5mg each of THC, CBD and CBG, and 1906 Genius 2.5mg of each per drop. Reaching the 20mg in Cuttler's nearly THC-free tincture through any of the four below means swallowing 10 to 20mg of THC along the way.

The table prices that, using menu figures read October 21 to November 4, 2026 on our Camino and 1906 reviews and our Papa and Barkley comparison. Tier names are the ladder on our dosing guide: moderate 5 to 15mg, high 15 to 30mg, 30mg and above very high.

The most expensive route to the trial dose is the product sold for thinking.

Memory is the finding that travels worst. Cuttler's tincture measured under 0.001mg of THC per gram, and THC has an established verbal memory problem: Englund's 46 infrequent users showed impaired delayed recall on 10mg of vaporized THC. Cuttler raises the question of whether CBG offsets that, and we found no trial answering it. 1906's Genius page promised "cognitive focus, memory enhancement, and calm concentration" when we checked it on October 22, with 5mg of THC in the two-drop serving. We still rank Genius first on our focus list, on the caffeine and L-theanine, and we price its CBG at zero, the same way our pain ranking prices Wyld Pear's. Our CBN piece found the same trial-dose gap one cannabinoid over.

The THC-free route is a hemp tincture or gummy, and Emerson's paper puts commercial products at 2 to 33mg a dose. Whether hemp CBG above the trace-THC cap survives December 11 hangs on FDA lists that our hemp ban timeline records as unpublished on November 2.

What CBG trials are running now?

ClinicalTrials.gov returned 19 entries for cannabigerol on November 7, 2026, some naming it only in passing, and none with results posted: 7 completed, 4 active but closed to enrollment, 2 recruiting, 2 not yet recruiting, 2 terminated and 2 of unknown status. Recruiting now are a Brazilian trial in adolescents with ADHD and a Hershey Medical Center neuropathy study.

Stanford's planned study is the one built on a plain CBG gummy: 25mg of hemp CBG in a gelatin chew after bladder cancer surgery, listed to start in July 2027. If Arkansas does report a benefit at 80mg, the dose line still applies: none of the four products in our table gets there with less than 40mg of THC.